ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).

被引：3
|
作者：
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Holzbeierlein, Jeffrey M.
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Yakovlevich
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Chen, Lucy F.
Stenzl, Arnulf
机构：
[1] Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[4] Univ Kansas, Med Ctr, Westwood, KS USA
[5] Lille Univ, Univ Hosp Ctr, Dept Urol, Lille, France
[6] Monash Hlth, Melbourne, Vic, Australia
[7] Hosp Clin Barcelona, Dept Urol, Barcelona, Spain
[8] Hertzen Moscow Canc Res Inst, Moscow, Russia
[9] Osaka City Univ, Dept Urol, Grad Sch Med, Osaka, Japan
[10] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[11] Pfizer Inc, San Diego, CA USA
[12] Astellas Pharma Inc, Leiden, Netherlands
[13] Astellas Pharma Inc, Northbrook, IL USA
[14] Eberhard Karls Univ Tubingen, Univ Hosp, Dept Urol, Tubingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5048
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
    Armstrong, Andrew J.
    Shore, Neal D.
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1361 - 1370
  • [22] KEYNOTE-991: PHASE 3 STUDY OF PEMBROLIZUMAB PLUS ENZALUTAMIDE AND ANDROGEN DEPRIVATION THERAPY (ADT) FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Gratzke, Christian
    Gratzke, Christian
    Gratzke, Christian
    Niu, Cuizhen
    Poehlein, Christian
    Burgents, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A211 - A211
  • [23] The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
    Armstrong, Andrew J.
    Iguchi, Taro
    Azad, Arun A.
    Villers, Arnauld
    Alekseev, Boris
    Petrylak, Daniel P.
    Szmulewitz, Russell Z.
    Alcaraz, Antonio
    Shore, Neal D.
    Holzbeierlein, Jeffrey
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Haas, Gabriel P.
    Gourgiotti, Georgia
    El-Chaar, Nader
    Stenzl, Arnulf
    EUROPEAN UROLOGY, 2023, 84 (02) : 229 - 241
  • [24] Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
    Jiang, W.
    Qu, S.
    Liu, Y.
    Yao, X.
    Liu, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 276 - 276
  • [25] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
    Gratzke, C. J.
    Ozguroglu, M.
    Peer, A.
    Sendur, M. A. N.
    Retz, M.
    Goh, J. C. H.
    Loidl, W. C.
    Jayram, G.
    Byun, S-S.
    Kwak, C.
    Kwiatkowski, M.
    Kopp, R. Manneh
    Limon, J. C. Vazquez
    Penagos, J. F. Escobar
    De Giorgi, U. F. F.
    Trindade, K. M. D.
    Niu, C.
    Liu, Y.
    Poehlein, C. H.
    Rodriguez, J. M. Piulats
    ANNALS OF ONCOLOGY, 2023, 34 : S957 - S958
  • [26] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses EDITORIAL COMMENT
    Smoragiewicz, Martin
    Emmenegger, Urban
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1370 - 1370
  • [27] Randomized trial of androgen deprivation therapy (ADT) plus enzalutamide (Arm A) versus ADT plus bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
    Vaishampayan, U. N.
    Heilbrun, L.
    Monk, P.
    Sonpavde, G.
    Tejwani, S.
    Heath, E. I.
    Fontana, J.
    Chinni, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES
    Sharifi, Nima
    Azad, Arun A.
    Patel, Mona
    Hearn, Jason W. D.
    Wozniak, Michele
    Zohren, Fabian
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    CELL REPORTS MEDICINE, 2024, 5 (08)
  • [29] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
    Iguchi, Taro
    Kimura, Go
    Fukasawa, Satoshi
    Suzuki, Hiroyoshi
    Uemura, Hiroji
    Nishimura, Kazuo
    Matsumoto, Hiroaki
    Yokomizo, Akira
    Armstrong, Andrew J.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Kunieda, Futoshi
    Stenzl, Arnulf
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (07) : 765 - 773
  • [30] Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
    Petrylak, D. P.
    Azad, A. A.
    Szmulewitz, R. Z.
    Iguchi, T.
    Shore, N. D.
    Holzbeierlein, J.
    Alekseev, B.
    El-Chaar, N. N.
    Rosbrook, B.
    Ma, J.
    Zohren, F.
    Haas, G. P.
    Stenzl, A.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1183 - S1184
12345